Evogene Historical Cash Flow
| EVGN Stock | USD 1.67 0.05 3.09% |
Analysis of Evogene cash flow over time is an excellent tool to project Evogene future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 25.9 M or Other Cashflows From Financing Activities of 11.1 M as it is a great indicator of Evogene ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Evogene latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Evogene is a good buy for the upcoming year.
Evogene |
About Evogene Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Evogene balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Evogene's non-liquid assets can be easily converted into cash.
Evogene Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Evogene to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Evogene operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Evogene's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Evogene current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.At this time, Evogene's Total Cashflows From Investing Activities is very stable compared to the past year. As of the 26th of November 2024, Sale Purchase Of Stock is likely to grow to about 10.7 M, though Change In Cash is likely to grow to (7.8 M).
Evogene cash flow statement Correlations
Click cells to compare fundamentals
Evogene Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evogene cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (895K) | (912K) | (92K) | (474K) | 490K | 514.5K | |
| Change In Cash | 28.9M | 11.5M | (13.9M) | (3.3M) | (8.2M) | (7.8M) | |
| Stock Based Compensation | 1.6M | 4.1M | 2.6M | 1.2M | 1.9M | 2.0M | |
| Free Cash Flow | (18.3M) | (20.2M) | (25.6M) | (24.8M) | (22.4M) | (23.5M) | |
| Change In Working Capital | (997K) | (1.4M) | 1.7M | (771K) | (400K) | (420K) | |
| Begin Period Cash Flow | 5.8M | 34.7M | 46.2M | 32.3M | 29.0M | 25.9M | |
| Other Cashflows From Financing Activities | (97K) | 2.4M | 1.3M | 125K | 10.5M | 11.1M | |
| Depreciation | 2.8M | 2.7M | 2.2M | 2.6M | 2.6M | 2.5M | |
| Other Non Cash Items | (1.6M) | 1.3M | (906K) | 3.1M | 321K | 337.1K | |
| Capital Expenditures | 900K | 682K | 724K | 1.2M | 785K | 1.2M | |
| Total Cash From Operating Activities | (17.4M) | (19.5M) | (24.8M) | (23.7M) | (21.6M) | (22.7M) | |
| Change To Account Receivables | 88K | (150K) | (59K) | (67K) | (1.5M) | (1.4M) | |
| Net Income | (19.1M) | (26.2M) | (30.4M) | (29.8M) | (26.0M) | (27.3M) | |
| Total Cash From Financing Activities | 9.0M | 20.4M | 30.3M | 9.3M | 18.2M | 12.2M | |
| End Period Cash Flow | 34.7M | 46.2M | 32.3M | 29.0M | 20.8M | 26.8M | |
| Change To Liabilities | (167K) | (368K) | 753K | (716K) | (644.4K) | (612.2K) | |
| Total Cashflows From Investing Activities | 37.1M | 9.4M | (20.4M) | 13.3M | 15.3M | 16.0M | |
| Investments | 38.0M | 10.1M | (19.7M) | 13.3M | (4.4M) | (4.2M) | |
| Change To Operating Activities | (918K) | (931K) | 1.1M | 486K | 558.9K | 586.8K | |
| Change To Netincome | (1.3M) | 2.6M | (936K) | 1.2M | 1.0M | 984.1K |
Pair Trading with Evogene
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evogene position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evogene will appreciate offsetting losses from the drop in the long position's value.Moving together with Evogene Stock
| 0.82 | ME | 23Andme Holding | PairCorr |
| 0.89 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Evogene Stock
| 0.63 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.5 | RNXT | RenovoRx | PairCorr |
| 0.45 | NXGLW | NexGel Warrant | PairCorr |
| 0.4 | KZR | Kezar Life Sciences | PairCorr |
| 0.35 | MLYS | Mineralys Therapeutics, | PairCorr |
The ability to find closely correlated positions to Evogene could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evogene when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evogene - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evogene to buy it.
The correlation of Evogene is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evogene moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evogene moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evogene can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.46) | Revenue Per Share 1.881 | Quarterly Revenue Growth 0.398 | Return On Assets (0.28) | Return On Equity (0.82) |
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.